RAPT Therapeutics (NASDAQ:RAPT – Get Rating) had its target price cut by HC Wainwright from $43.00 to $41.00 in a report issued on Friday morning, The Fly reports. Several other brokerages have also recently commented on RAPT. JPMorgan Chase & Co. cut their price target on shares of RAPT Therapeutics from $48.00 to $42.00 and […]
RAPT Therapeutics (NASDAQ:RAPT – Get Rating) had its price objective trimmed by HC Wainwright from $43.00 to $41.00 in a report released on Friday, The Fly reports. RAPT has been the topic of a number of other reports. JPMorgan Chase & Co. lowered their price objective on RAPT Therapeutics from $48.00 to $42.00 and set […]
Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Rating) have earned a consensus recommendation of “Buy” from the nine brokerages that are covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have covered the stock in the last […]
RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Rating) gapped up prior to trading on Monday . The stock had previously closed at $16.77, but opened at $18.19. RAPT Therapeutics shares last traded at $18.88, with a volume of 145,519 shares changing hands. Analysts Set New Price Targets A number of research firms have issued reports on […]
HC Wainwright reissued their buy rating on shares of RAPT Therapeutics (NASDAQ:RAPT – Get Rating) in a research report sent to investors on Thursday, Benzinga reports. HC Wainwright currently has a $43.00 price objective on the stock. RAPT has been the subject of several other reports. JPMorgan Chase & Co. cut their price objective on […]